Evidence map›Paper›PMID 41803288›Full record

ReviewDiabetologia2026

Continuous glucose monitoring as a tool in early-stage type 1 diabetes.

Alice L J Carr, Hannah Sutton, Rikke M Agesen, Ezio Bonifacio, Emanuele Bosi, Pieter Gillard, Rabbi Swaby, Jurgen Vercauteren, Rachel E J Besser

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alice L J CarrAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. acarr1@ualberta.ca.
Hannah SuttonDiabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Bukhman Centre for Research Excellence in Type 1 Diabetes, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Rikke M AgesenNovo Nordisk A/S, Søborg, Denmark.
Ezio BonifacioCenter for Regenerative Therapies Dresden (CRTD), Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
Emanuele BosiDiabetes Research Institute, San Raffaele Hospital, Milan, Italy.
Pieter GillardDepartment of Endocrinology, University Hospitals Leuven, Leuven, Belgium.
Rabbi SwabyDiabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Bukhman Centre for Research Excellence in Type 1 Diabetes, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Jurgen VercauterenDepartment of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Rachel E J BesserDiabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Bukhman Centre for Research Excellence in Type 1 Diabetes, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. rachel.besser@well.ox.ac.uk.

Funding

Innovative Health Initiative Joint Undertaking 101132379JDRF/Wellcome Strategic Award 107212/A/15/ZJDRF/Wellcome Strategic Award 4-SRA-2017-473-A-N
6 · The paper itself

Abstract

Continuous glucose monitoring (CGM) has transformed diabetes management by providing continuous, real-time insights into glucose dynamics, while enhancing the lived experience of individuals with type 1 diabetes. In established type 1 diabetes, CGM-derived measures of glucose management, such as time in range, time above range, time below range and glycaemic variability, have become integral tools to optimise therapy, reduce episodes of hypoglycaemia and guide clinical decision-making. More recently, CGM has emerged as a promising tool to detect early hyperglycaemia and other glucose abnormalities in individuals with early-stage type 1 diabetes, for whom current screening and staging methods, including fasting glucose, HbA

Indexed as

Blood GlucoseContinuous Glucose MonitoringDiabetes Mellitus, Type 1Blood Glucose Self-MonitoringGlycated HemoglobinHumansHyperglycemiaBlood GlucoseGlycated HemoglobinContinuous glucose monitoringProgressionReviewStage 1 diabetesStage 2 diabetesType 1 diabetes

Identifiers

PMID41803288
PMCPMC13109206

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.